Neoadjuvant chemotherapy in triple-negative breast cancer

A multicentric retrospective observational study in real-life setting

Teresa Gamucci, Laura Pizzuti, Isabella Sperduti, Lucia Mentuccia, Angela Vaccaro, Luca Moscetti, Paolo Marchetti, Luisa Carbognin, Andrea Michelotti, Laura Iezzi, Alessandra Cassano, Antonino Grassadonia, Antonio Astone, Andrea Botticelli, Emanuela Magnolfi, Luigi Di Lauro, Domenico Sergi, Paola Fuso, Nicola Tinari, Maddalena Barba & 10 others Marcello Maugeri-Saccà, Elisabetta Landucci, Francesca Conti, Giuseppe Sanguineti, Michele De Tursi, Gianni Iafrate, Antonio Giordano, Gennaro Ciliberto, Clara Natoli, Patrizia Vici

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We aimed to assess the efficacy of neoadjuvant chemotherapy (NACT) in a cohort of 213 triple-negative breast cancer (TNBC) patients treated in real-world practice at eight Italian cancer centers. We computed descriptive statistics for all the variable of interest. Factors testing significant in univariate analysis were included in multivariate models. Survival data were compared by Kaplan–Meier curves and log-rank test. The median follow-up was 45 months. We observed 60 (28.2%) pathological complete response (pCR). The sequential anthracyclines-taxanes-based regimens produced the highest rate of pCR (42.6%), followed by concomitant anthracycline-taxane (24.2%), and other regimens (15.6%) (p = 0.008). When analyzing the role of baseline Ki-67, a 50% cut-off was the optimal threshold value for pCR prediction (p = 0.0005). The 5-year disease-free survival (DFS) was 57.3% and the 5-year overall survival (OS) was 70.8%. In patients not achieving pCR, the optimal Ki-67 variation between biopsy and surgical specimen with prognostic relevance on long-term outcomes was 13% (p = 0.04). Patients with a Ki-67 reduction (rKi-67)<13% had worse outcomes compared to those who experienced pCR or a rKi-67≥13%. The number of NACT cycles also affected long-term outcomes (5-year DFS 65.7% vs 51.6% in patients having received >6 cycles compared with their counterparts, p = 0.02). In multivariate analysis, node status, grading, and bio-pathological treatment response (including pCR and rKi-67) impacted DFS and OS. Our results confirmed the advantage conferred by more than 6 cycles of a sequential antracycline-taxane-based NACT. Higher baseline Ki-67 values shows greater predictive significance on pathogical response, while the rKi-67 plays a prognostic role on long-term outcomes.

Original languageEnglish
Pages (from-to)2313-2323
Number of pages11
JournalJournal of Cellular Physiology
Volume233
Issue number3
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Triple Negative Breast Neoplasms
Chemotherapy
Anthracyclines
Observational Studies
Retrospective Studies
Drug Therapy
Taxoids
Disease-Free Survival
Survival
Biopsy
Statistics
Testing
Multivariate Analysis
taxane
Neoplasms
Therapeutics

Keywords

  • long-term outcomes
  • neoadjuvant chemotherapy
  • pathological complete response
  • rKi-67
  • triple-negative breast cancer

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Neoadjuvant chemotherapy in triple-negative breast cancer : A multicentric retrospective observational study in real-life setting. / Gamucci, Teresa; Pizzuti, Laura; Sperduti, Isabella; Mentuccia, Lucia; Vaccaro, Angela; Moscetti, Luca; Marchetti, Paolo; Carbognin, Luisa; Michelotti, Andrea; Iezzi, Laura; Cassano, Alessandra; Grassadonia, Antonino; Astone, Antonio; Botticelli, Andrea; Magnolfi, Emanuela; Di Lauro, Luigi; Sergi, Domenico; Fuso, Paola; Tinari, Nicola; Barba, Maddalena; Maugeri-Saccà, Marcello; Landucci, Elisabetta; Conti, Francesca; Sanguineti, Giuseppe; De Tursi, Michele; Iafrate, Gianni; Giordano, Antonio; Ciliberto, Gennaro; Natoli, Clara; Vici, Patrizia.

In: Journal of Cellular Physiology, Vol. 233, No. 3, 01.03.2018, p. 2313-2323.

Research output: Contribution to journalArticle

Gamucci, T, Pizzuti, L, Sperduti, I, Mentuccia, L, Vaccaro, A, Moscetti, L, Marchetti, P, Carbognin, L, Michelotti, A, Iezzi, L, Cassano, A, Grassadonia, A, Astone, A, Botticelli, A, Magnolfi, E, Di Lauro, L, Sergi, D, Fuso, P, Tinari, N, Barba, M, Maugeri-Saccà, M, Landucci, E, Conti, F, Sanguineti, G, De Tursi, M, Iafrate, G, Giordano, A, Ciliberto, G, Natoli, C & Vici, P 2018, 'Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting', Journal of Cellular Physiology, vol. 233, no. 3, pp. 2313-2323. https://doi.org/10.1002/jcp.26103
Gamucci, Teresa ; Pizzuti, Laura ; Sperduti, Isabella ; Mentuccia, Lucia ; Vaccaro, Angela ; Moscetti, Luca ; Marchetti, Paolo ; Carbognin, Luisa ; Michelotti, Andrea ; Iezzi, Laura ; Cassano, Alessandra ; Grassadonia, Antonino ; Astone, Antonio ; Botticelli, Andrea ; Magnolfi, Emanuela ; Di Lauro, Luigi ; Sergi, Domenico ; Fuso, Paola ; Tinari, Nicola ; Barba, Maddalena ; Maugeri-Saccà, Marcello ; Landucci, Elisabetta ; Conti, Francesca ; Sanguineti, Giuseppe ; De Tursi, Michele ; Iafrate, Gianni ; Giordano, Antonio ; Ciliberto, Gennaro ; Natoli, Clara ; Vici, Patrizia. / Neoadjuvant chemotherapy in triple-negative breast cancer : A multicentric retrospective observational study in real-life setting. In: Journal of Cellular Physiology. 2018 ; Vol. 233, No. 3. pp. 2313-2323.
@article{9177497f0e3f4a7799c352a79f1238f2,
title = "Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting",
abstract = "We aimed to assess the efficacy of neoadjuvant chemotherapy (NACT) in a cohort of 213 triple-negative breast cancer (TNBC) patients treated in real-world practice at eight Italian cancer centers. We computed descriptive statistics for all the variable of interest. Factors testing significant in univariate analysis were included in multivariate models. Survival data were compared by Kaplan–Meier curves and log-rank test. The median follow-up was 45 months. We observed 60 (28.2{\%}) pathological complete response (pCR). The sequential anthracyclines-taxanes-based regimens produced the highest rate of pCR (42.6{\%}), followed by concomitant anthracycline-taxane (24.2{\%}), and other regimens (15.6{\%}) (p = 0.008). When analyzing the role of baseline Ki-67, a 50{\%} cut-off was the optimal threshold value for pCR prediction (p = 0.0005). The 5-year disease-free survival (DFS) was 57.3{\%} and the 5-year overall survival (OS) was 70.8{\%}. In patients not achieving pCR, the optimal Ki-67 variation between biopsy and surgical specimen with prognostic relevance on long-term outcomes was 13{\%} (p = 0.04). Patients with a Ki-67 reduction (rKi-67)<13{\%} had worse outcomes compared to those who experienced pCR or a rKi-67≥13{\%}. The number of NACT cycles also affected long-term outcomes (5-year DFS 65.7{\%} vs 51.6{\%} in patients having received >6 cycles compared with their counterparts, p = 0.02). In multivariate analysis, node status, grading, and bio-pathological treatment response (including pCR and rKi-67) impacted DFS and OS. Our results confirmed the advantage conferred by more than 6 cycles of a sequential antracycline-taxane-based NACT. Higher baseline Ki-67 values shows greater predictive significance on pathogical response, while the rKi-67 plays a prognostic role on long-term outcomes.",
keywords = "long-term outcomes, neoadjuvant chemotherapy, pathological complete response, rKi-67, triple-negative breast cancer",
author = "Teresa Gamucci and Laura Pizzuti and Isabella Sperduti and Lucia Mentuccia and Angela Vaccaro and Luca Moscetti and Paolo Marchetti and Luisa Carbognin and Andrea Michelotti and Laura Iezzi and Alessandra Cassano and Antonino Grassadonia and Antonio Astone and Andrea Botticelli and Emanuela Magnolfi and {Di Lauro}, Luigi and Domenico Sergi and Paola Fuso and Nicola Tinari and Maddalena Barba and Marcello Maugeri-Sacc{\`a} and Elisabetta Landucci and Francesca Conti and Giuseppe Sanguineti and {De Tursi}, Michele and Gianni Iafrate and Antonio Giordano and Gennaro Ciliberto and Clara Natoli and Patrizia Vici",
year = "2018",
month = "3",
day = "1",
doi = "10.1002/jcp.26103",
language = "English",
volume = "233",
pages = "2313--2323",
journal = "Journal of cellular and comparative physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy in triple-negative breast cancer

T2 - A multicentric retrospective observational study in real-life setting

AU - Gamucci, Teresa

AU - Pizzuti, Laura

AU - Sperduti, Isabella

AU - Mentuccia, Lucia

AU - Vaccaro, Angela

AU - Moscetti, Luca

AU - Marchetti, Paolo

AU - Carbognin, Luisa

AU - Michelotti, Andrea

AU - Iezzi, Laura

AU - Cassano, Alessandra

AU - Grassadonia, Antonino

AU - Astone, Antonio

AU - Botticelli, Andrea

AU - Magnolfi, Emanuela

AU - Di Lauro, Luigi

AU - Sergi, Domenico

AU - Fuso, Paola

AU - Tinari, Nicola

AU - Barba, Maddalena

AU - Maugeri-Saccà, Marcello

AU - Landucci, Elisabetta

AU - Conti, Francesca

AU - Sanguineti, Giuseppe

AU - De Tursi, Michele

AU - Iafrate, Gianni

AU - Giordano, Antonio

AU - Ciliberto, Gennaro

AU - Natoli, Clara

AU - Vici, Patrizia

PY - 2018/3/1

Y1 - 2018/3/1

N2 - We aimed to assess the efficacy of neoadjuvant chemotherapy (NACT) in a cohort of 213 triple-negative breast cancer (TNBC) patients treated in real-world practice at eight Italian cancer centers. We computed descriptive statistics for all the variable of interest. Factors testing significant in univariate analysis were included in multivariate models. Survival data were compared by Kaplan–Meier curves and log-rank test. The median follow-up was 45 months. We observed 60 (28.2%) pathological complete response (pCR). The sequential anthracyclines-taxanes-based regimens produced the highest rate of pCR (42.6%), followed by concomitant anthracycline-taxane (24.2%), and other regimens (15.6%) (p = 0.008). When analyzing the role of baseline Ki-67, a 50% cut-off was the optimal threshold value for pCR prediction (p = 0.0005). The 5-year disease-free survival (DFS) was 57.3% and the 5-year overall survival (OS) was 70.8%. In patients not achieving pCR, the optimal Ki-67 variation between biopsy and surgical specimen with prognostic relevance on long-term outcomes was 13% (p = 0.04). Patients with a Ki-67 reduction (rKi-67)<13% had worse outcomes compared to those who experienced pCR or a rKi-67≥13%. The number of NACT cycles also affected long-term outcomes (5-year DFS 65.7% vs 51.6% in patients having received >6 cycles compared with their counterparts, p = 0.02). In multivariate analysis, node status, grading, and bio-pathological treatment response (including pCR and rKi-67) impacted DFS and OS. Our results confirmed the advantage conferred by more than 6 cycles of a sequential antracycline-taxane-based NACT. Higher baseline Ki-67 values shows greater predictive significance on pathogical response, while the rKi-67 plays a prognostic role on long-term outcomes.

AB - We aimed to assess the efficacy of neoadjuvant chemotherapy (NACT) in a cohort of 213 triple-negative breast cancer (TNBC) patients treated in real-world practice at eight Italian cancer centers. We computed descriptive statistics for all the variable of interest. Factors testing significant in univariate analysis were included in multivariate models. Survival data were compared by Kaplan–Meier curves and log-rank test. The median follow-up was 45 months. We observed 60 (28.2%) pathological complete response (pCR). The sequential anthracyclines-taxanes-based regimens produced the highest rate of pCR (42.6%), followed by concomitant anthracycline-taxane (24.2%), and other regimens (15.6%) (p = 0.008). When analyzing the role of baseline Ki-67, a 50% cut-off was the optimal threshold value for pCR prediction (p = 0.0005). The 5-year disease-free survival (DFS) was 57.3% and the 5-year overall survival (OS) was 70.8%. In patients not achieving pCR, the optimal Ki-67 variation between biopsy and surgical specimen with prognostic relevance on long-term outcomes was 13% (p = 0.04). Patients with a Ki-67 reduction (rKi-67)<13% had worse outcomes compared to those who experienced pCR or a rKi-67≥13%. The number of NACT cycles also affected long-term outcomes (5-year DFS 65.7% vs 51.6% in patients having received >6 cycles compared with their counterparts, p = 0.02). In multivariate analysis, node status, grading, and bio-pathological treatment response (including pCR and rKi-67) impacted DFS and OS. Our results confirmed the advantage conferred by more than 6 cycles of a sequential antracycline-taxane-based NACT. Higher baseline Ki-67 values shows greater predictive significance on pathogical response, while the rKi-67 plays a prognostic role on long-term outcomes.

KW - long-term outcomes

KW - neoadjuvant chemotherapy

KW - pathological complete response

KW - rKi-67

KW - triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85035045931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035045931&partnerID=8YFLogxK

U2 - 10.1002/jcp.26103

DO - 10.1002/jcp.26103

M3 - Article

VL - 233

SP - 2313

EP - 2323

JO - Journal of cellular and comparative physiology

JF - Journal of cellular and comparative physiology

SN - 0021-9541

IS - 3

ER -